Sep 28, 2017
BEVERLY, MA--(Marketwired - September 28, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, reported today that the first patient has been dosed with BIV201, which is being studied ...
Sep 25, 2017
BEVERLY, MA--(Marketwired - September 25, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of R. Richard Wieland II, MBA as the Company's in...
Sep 14, 2017
BEVERLY, MA --(Marketwired - September 14, 2017) - In the news release, "First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites," issued earlier today by BioVie Inc. (OTCQB: BIVI), we are advised by the company that the title of the release should read "First Patient Enrolled ...